Roger Olofsson1, Jan Mattsson, Per Lindnér. 1. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. roger.olofsson@surgery.gu.se
Abstract
PURPOSE: The aim of the present study is to describe our experience with isolated limb perfusion (ILP) in the treatment of in-transit metastases of malignant melanoma and to determine prognostic factors for response, local progression, survival and toxicity. MATERIALS AND METHODS: A retrospective follow-up of all patients (n = 163) treated between January 1984 and December 2008 using data collected from individual patient records and the Swedish National Patient Register. RESULTS: Clinical response was evaluable in 155 patients, 65% had a complete response (CR) and 20% had a partial response (PR). Local progression occurred in 63% of the patients after a median time of 16 months. Negative prognostic factors in univariate analyses were proximal location of the primary tumour, >10 in-transit metastases and if there was no CR after ILP. In multivariate analysis, proximal location of the primary tumour and no CR after ILP were significant prognostic factors. Median cancer-specific survival was 30 months, and negative prognostic factors in univariate analyses were male gender, positive lymph node status, systemic metastases, bulky tumour, >10 in-transit metastases and if there was no CR after ILP. In multivariate analysis, positive lymph node status, bulky tumour and no CR after ILP were significant prognostic factors. A majority (97%) of the patients had a Wieberdink grade II-III local toxicity. Four patients underwent limb amputation after a median of 19 months, none because of toxicity. CONCLUSION: We found that ILP is a safe method with a high response rate for the treatment of patients with in-transit metastases of malignant melanoma.
PURPOSE: The aim of the present study is to describe our experience with isolated limb perfusion (ILP) in the treatment of in-transit metastases of malignant melanoma and to determine prognostic factors for response, local progression, survival and toxicity. MATERIALS AND METHODS: A retrospective follow-up of all patients (n = 163) treated between January 1984 and December 2008 using data collected from individual patient records and the Swedish National Patient Register. RESULTS: Clinical response was evaluable in 155 patients, 65% had a complete response (CR) and 20% had a partial response (PR). Local progression occurred in 63% of the patients after a median time of 16 months. Negative prognostic factors in univariate analyses were proximal location of the primary tumour, >10 in-transit metastases and if there was no CR after ILP. In multivariate analysis, proximal location of the primary tumour and no CR after ILP were significant prognostic factors. Median cancer-specific survival was 30 months, and negative prognostic factors in univariate analyses were male gender, positive lymph node status, systemic metastases, bulky tumour, >10 in-transit metastases and if there was no CR after ILP. In multivariate analysis, positive lymph node status, bulky tumour and no CR after ILP were significant prognostic factors. A majority (97%) of the patients had a Wieberdink grade II-III local toxicity. Four patients underwent limb amputation after a median of 19 months, none because of toxicity. CONCLUSION: We found that ILP is a safe method with a high response rate for the treatment of patients with in-transit metastases of malignant melanoma.
Authors: Tavis A Read; Aaron Smith; Janine Thomas; Michael David; Matthew Foote; Michael Wagels; Andrew Barbour; B Mark Smithers Journal: J Surg Oncol Date: 2018-03-12 Impact factor: 3.454
Authors: Junko Johansson; Roberta Kiffin; Ebru Aydin; Malin S Nilsson; Kristoffer Hellstrand; Per Lindnér; Peter Naredi; Roger Olofsson Bagge; Anna Martner Journal: Oncoimmunology Date: 2019-11-03 Impact factor: 8.110
Authors: Hansje-Eva Teulings; Esther P M Tjin; Karina J Willemsen; Stephanie van der Kleij; Sylvia Ter Meulen; E Helen Kemp; Gabrielle Krebbers; Carel J M van Noesel; Cornelis L M C Franken; Jan W Drijfhout; Cornelis J M Melief; Ludmila Nieuweboer-Krobotova; Omgo E Nieweg; Jos A van der Hage; J P Wietze van der Veen; Germaine N Relyveld; Rosalie M Luiten Journal: Oncoimmunology Date: 2018-01-15 Impact factor: 8.110
Authors: Emmanuel M Gabriel; Minhyung Kim; Daniel T Fisher; Colin Powers; Kristopher Attwood; Sanjay P Bagaria; Keith L Knutson; Joseph J Skitzki Journal: Sci Rep Date: 2020-08-06 Impact factor: 4.379